Epithelial Origin Or Derivative Patents (Class 435/371)
-
Publication number: 20120237607Abstract: The invention is directed to immortalized cell compositions and compositions derived therefrom. The invention is further directed to methods of making and using such immortalized cell compositions and compositions derived therefrom. Such immortalized cell compositions include but are not limited to Immortalized Amnion-derived Multipotent Progenitor cells (herein referred to as I-AMP cells) and conditioned media derived therefrom (herein referred to as I-Amnion-derived Cellular Cytokine Solution or I-ACCS).Type: ApplicationFiled: February 29, 2012Publication date: September 20, 2012Inventors: Randall G. Rupp, Linda O. Palladino
-
Publication number: 20120237535Abstract: The invention relates to immunogenic conjugates comprising an immunogenic region of human papilloma virus E7 protein and the fibronectin EDA region, as well to compositions comprising said conjugates and to dendritic cells obtained by stimulation with said conjugates and compositions. Moreover, the invention relates to methods for the treatment of diseases caused by the human papilloma virus (HPV) using said conjugates, compositions and dendritic cells.Type: ApplicationFiled: September 10, 2010Publication date: September 20, 2012Applicant: PROYECTO DE BIOMEDICINA CIMA, S.L.Inventors: Pedro Berraondo-Lopez, Juan Jose Lasarte Sagastibelza, Christina Mansilla Puerta, Jesus Maria Prieto Valtuena, Pablo Sarobe Ugarriza
-
Publication number: 20120238620Abstract: The invention provides an isolated nucleic acid encoding a polypeptide capable of inhibiting angiogenesis or neovascularization, wherein the nucleic acid comprises a first polynucleotide sequence comprising a coding sequence at least 95 percent identical to a sequence selected from the group consisting of a polynucleotide SEQ ID NO:6, a polynucleotide that encodes a polypeptide of SEQ ID NO:12, and a polynucleotide that encodes a fragment of the polypeptide of SEQ ID NO:12; and wherein the nucleic acid does not encode for the amino acid sequence of amino acids 71-93 of SEQ ID NO:1. Pharmaceutical compositions, vectors, and methods for inhibiting neovascularization or angiogenesis comprising or utilizing the nucleic acids also are provided.Type: ApplicationFiled: September 12, 2011Publication date: September 20, 2012Inventors: Paul Schimmel, Keisuke Wakasugi, Martin Friedlander
-
Publication number: 20120237981Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars. In one aspect, the invention provides delayed release compositions comprising a desired ingredient coated by a latex polymer coating.Type: ApplicationFiled: May 29, 2012Publication date: September 20, 2012Applicant: VERENIUM CORPORATIONInventors: WALTER CALLEN, TOBY RICHARDSON, GERHARD FREY, KEVIN GRAY, JANNE S. KEROVUO, MALGORZATA SLUPSKA, NELSON BARTON, EILEEN O'DONOGHUE, CARL MILLER
-
Patent number: 8268303Abstract: This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.Type: GrantFiled: August 17, 2010Date of Patent: September 18, 2012Assignee: Advanced Cell Technology, Inc.Inventors: Irina V. Klimanskaya, Robert P. Lanza
-
Publication number: 20120196275Abstract: Disclosed are methods of preparing multi-cellular three-dimensional tissue constructs, that include fibroblasts, endothelial cells, lymphocytes and epithelial cells. The present methods may include embedding fibroblasts and endothelial cells in a matrix enriched with gut basement membrane proteins to form a cell containing matrix that is then added to a bioreactor and exposed to epithelial cells and activated lymphocytes as the cell cultures. Also provided are the tissue constructs formed from such methods, a matrix enriched with gut basement membrane proteins and kits that include the same. Further provided are methods of measuring toxicity of a pathogen or commensal organisms, chemosensitivity of tissues to a toxic material and inflammatory conditions, which use the present multi-cellular three-dimensional tissue constructs.Type: ApplicationFiled: January 27, 2012Publication date: August 2, 2012Inventors: Rosangela MEZGHANNI, Alessio Fasano, Marcelo Sztein
-
Publication number: 20120190109Abstract: The invention relates to a process for obtention of myofibroblasts. According to this process: (a) a sample of cells essentially comprising fibroblasts is prepared; and (b) this sample of cells is cultured in a serum-free culture medium. The main purpose addressed by the invention is to obtain a population of myofibroblasts, the characteristics whereof facilitate any study of these cells, and in particular as pure as possible a population of myofibroblasts. Some examples of application of the invention are: identification of biomarkers of myofibroblasts, identification of therapeutic targets, identification and validation of anticancer compounds, and an in vitro model for the screening of pharmaceutical or cosmetic compounds.Type: ApplicationFiled: July 2, 2010Publication date: July 26, 2012Inventors: Nicolas Jacques Rouyer, Robert Barthel
-
Publication number: 20120189595Abstract: The invention relates to the field of stem cells and, specially, to the reprogramming of adult somatic cells; to obtain pluripotent cells by the transfection of specific genes. Thus, the invention provides induced pluripotent stem cells (iPS) and methods of obtaining and using them.Type: ApplicationFiled: September 25, 2009Publication date: July 26, 2012Applicant: SALK INSTITUTE FOR BIOLOGICAL STUDIESInventors: Angel Raya, Trond Aasen, Juan Carlos Izpisua Belmonte
-
Patent number: 8227245Abstract: This invention relates to multipotent stem cells, purified from the peripheral tissue of mammals, and capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.Type: GrantFiled: April 18, 2008Date of Patent: July 24, 2012Assignee: McGill UniversityInventors: Jean Toma, Mahnaz Akhavan, Karl J. L. Fernandes, Mathieu Fortier, Freda Miller
-
Patent number: 8211700Abstract: This invention relates to methods of inducing differential stress resistance in a subject with cancer by starving the subject for a short term, administering a cell growth inhibitor to the subject, or reducing the caloric or glucose intake by the subject. The induced differential stress resistance results in improved resistance to cytotoxicity in normal cells, which, in turn, reduces cytotoxic side-effects due to chemotherapy, as well as improved effectiveness of chemotherapeutic agents.Type: GrantFiled: March 28, 2008Date of Patent: July 3, 2012Assignee: University of Southern CaliforniaInventor: Valter Longo
-
Patent number: 8211631Abstract: A population of iPS cells derived from somatic cells from a spinal muscular atrophy patient is disclosed. In one embodiment of the invention, the cells have been cultured to produce neural cells. In another embodiment, the invention is a method of testing compounds for their ability to modify cellular SMN levels comprising the steps of obtaining a population of iPS cells derived from a spinal muscular atrophy patient or cells derived from the iPS cells, and examining the effect of a test compound on SMN levels.Type: GrantFiled: December 18, 2009Date of Patent: July 3, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Clive Svendsen, Allison Ebert
-
Patent number: 8206980Abstract: A method for culture of hair follicular dermal sheath cells or precursor cells thereof which are potent cellular materials for such as hair regeneration by cell transplantation is provided. That is, by performing culture in an animal cell culture medium supplemented with platelet-derived growth factor AA (PDGF-AA) and fibroblast growth factor 2 (FGF2), hair follicular dermal sheath cells are proliferated while sustaining their function, or hair follicular dermal sheath precursor cells are differentiated into dermal sheath cells and proliferated.Type: GrantFiled: October 2, 2006Date of Patent: June 26, 2012Assignees: Phoenixbio Co., Ltd., Biointegrence Inc.Inventors: Koei Toyoshima, Mikaru Matsunaga, Katsutoshi Yoshizato
-
Publication number: 20120149598Abstract: The present invention provides a feeder cell for target cell induction, wherein the feeder cell is transduced with an immortalizing gene and a suicide gene; and a production process for a target cell sheet using the feeder cell for target cell induction.Type: ApplicationFiled: January 22, 2010Publication date: June 14, 2012Inventors: Tomoyuki Inoue, Fumihiko Takamatsu, Naoyuki Maeda, Kohji Nishida, Yasuo Tano
-
Publication number: 20120148559Abstract: The invention provides deimmunized mutant proteins having reduced immunogenicity while exhibiting substantially the same or greater biological activity as the proteins of interst from which they are derived, as exemplified by mutant L-asparaginase that comprises amino acid substitutions compared to wild type L-asparaginase. The invention further provides methods for screening mutant deimmunized proteins that have substantially the same or greater biological activity as a protein of interest, and methods for reducing immunogenicity, without substantially reducing biological activity, of a protein of interest. The invention's compositions and methods are useful in, for example, therapeutic applications by minimizing adverse immune responses by the host mammalian subjects to the protein of interest.Type: ApplicationFiled: November 30, 2011Publication date: June 14, 2012Applicant: Board of Regents The University of Texas SystemInventors: George Georgiou, Jason Cantor, Tae Hyeon Yoo
-
Patent number: 8197804Abstract: The invention is directed to methods for treating nervous system injury and disease, in particular traumatic brain injury and degenerative nervous system disease. Such methods utilize novel compositions, including but not limited to trophic factor-secreting extraembryonic cells (herein referred to as TSE cells), including, but not limited to, amnion-derived multipotent progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine solution or ACCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: May 13, 2008Date of Patent: June 12, 2012Assignee: Stemnion, Inc.Inventors: George L. Sing, Vivienne S. Marshall, Diana L. Clarke
-
Publication number: 20120141573Abstract: The invention provides nucleic acid and polypeptide sequences encoding antibody based scaffolds such as full antibodies, antibody Fab fragments, single chain antibodies, soluble VEGF receptor-Fc fusion proteins, and/or anti-angiogenic PDGF receptors. Also encompassed are cell lines encoding such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors. The invention also provides encapsulated cell therapy devices that are capable of delivering such anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors as well as methods of using these devices to deliver the anti-angiogenic antibody scaffolds, VEGF receptors, and/or PDGF receptors to medically treat disorders in patients, including ophthalmic, vascular, inflammatory, and cell proliferation diseases.Type: ApplicationFiled: November 30, 2011Publication date: June 7, 2012Inventors: Vincent Ling, Arne M. Nystuen, Weng Tao, Paul Stabila, Konard Kauper
-
Patent number: 8187875Abstract: The present disclosure describes the generation of neural cells and neurons from mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. Specifically, the present disclosure describes the generation of neuroprogenitor cells and differentiated dopaminergic neurons from ELSCs. The disclosed methods demonstrate the potential of ELSCs as a therapeutic tool, and may provide new therapeutic alternatives for various diseases, conditions, and injuries. Neuroprogenitor cells generated from ELSCs isolated from corneo-limbal tissue were transplanted into a rat model of Parkinson's disease, and were able to alleviate motor abnormalities in the rats for at least six months.Type: GrantFiled: August 10, 2006Date of Patent: May 29, 2012Assignee: Reliance Life Sciences Pvt. Ltd.Inventors: Geeta Ravindran, Harinarayana Rao
-
Publication number: 20120122212Abstract: The present disclosure provides methods and compositions to enhance reprogramming in human cells. In some cases, the method includes contacting human cells with an inhibitor of the TGF? pathway, for example a TGF? receptor (TGF?R) inhibitor in combination with one or more induction factors.Type: ApplicationFiled: March 5, 2010Publication date: May 17, 2012Inventors: Marica Grskovic, John Dimos, Berta Strulovici, Adel Bakhtiarova, Weidong Wang
-
Publication number: 20120122716Abstract: In some embodiments, the invention relates to a stable, long-term human ES cell line. In other aspects, the invention relates to methods for establishing a stable long-term ES cell line and methods for screening therapeutic treatments for inner ear diseases, such as Meniere's disease.Type: ApplicationFiled: November 14, 2011Publication date: May 17, 2012Inventors: DAVID LIM, SUNG-KYUN MOON, HELGE RASK-ANDERSEN, JOHNG S. RHIM
-
Publication number: 20120122213Abstract: In the field of biological technology, a stem cell culture method is provided. The method includes preparing an amniotic epithelial cell feeder layer that is not treated to lose the division ability; and seeding the stem cells onto the amniotic epithelial cell feeder layer, and culturing in a culture medium. The stem cell culture method according to the present invention does not require the treatment of the feeder layer cells to lose the division ability, and is thus simple and safe, thereby effectively solving the problem of contamination caused by animal-derived ingredients in culture of human stem cells at present, greatly reducing the culture cost of the stem cells, and providing a safe, effective, and inexpensive stem cell culture method for the industrialization of the stem cells in the future.Type: ApplicationFiled: May 4, 2010Publication date: May 17, 2012Inventors: Dongmei Lai, Weiwei Cheng, Lihe Guo, Tianjin Liu, Lizhen Jiang, Qin Huang
-
Patent number: 8173372Abstract: The detection of endothelial cell antibodies has been proven clinically important for successful organ transplantation. Disclosed are methods of isolating Tie-2+ and CD34? precursor endothelial cells for use in donor-specific crossmatching.Type: GrantFiled: May 16, 2003Date of Patent: May 8, 2012Assignee: AbSorber ABInventor: Suchitra Sumitran-Holgersson
-
Patent number: 8153359Abstract: An in vitro toxicity assay based on human blastocyst-derived stem cells for the detection of toxicity in the human species is provided, which enables novel detection of in vitro human toxicity for a substance and/or more efficiently detects human toxicity compared to non-human assays. Furthermore, the detection of toxicity for substances is enabled, which is known to display inter-species differences and the toxic effect was not detectable by toxicological tests in mice.Type: GrantFiled: October 2, 2007Date of Patent: April 10, 2012Assignee: Cellartis ABInventors: Raimund Strehl, Sarah Adler
-
Publication number: 20120083442Abstract: The present invention provides binding agents comprising peptides capable of binding myostatin and inhibiting its activity. In one embodiment the binding agent comprises at least one myostatin-binding peptide attached directly or indirectly to at least one vehicle such as a polymer or an Fc domain. The binding agents of the present invention produced increased lean muscle mass when administered to animals and decreased fat to muscle ratios. Therapeutic compositions containing the binding agents of the present invention are useful for treating muscle-wasting disorders and metabolic disorders including diabetes and obesity.Type: ApplicationFiled: December 2, 2011Publication date: April 5, 2012Applicant: AMGEN INC.Inventors: HQ HAN, HOSUNG MIN, THOMAS CHARLES BOONE
-
Publication number: 20120084871Abstract: The present invention provides, in part, NPC1L1 from various species. Methods of using the NPC1L1 polypeptides and polynucleotide set forth herein, e.g., in screening assays, are also set forth.Type: ApplicationFiled: February 14, 2011Publication date: April 5, 2012Applicant: Schering CorporationInventors: Scott Altmann, Xiaorui Yao, Kim Anne O'Neill, Brian E. Hawes
-
Publication number: 20120079616Abstract: The present invention provides human, rat and mouse NPC1L1 polypeptides and polynucleotides encoding the polypeptides. Also provided are methods for detecting agonists and antagonists of NPC1L1. Inhibitors of NPC1L1 can be used for inhibiting intestinal cholesterol absorption in a subject.Type: ApplicationFiled: October 12, 2011Publication date: March 29, 2012Applicant: Schering CorporationInventors: Scott W. Altmann, Nicholas J. Murgolo, Luquan Wang, Michael P. Graziano
-
Patent number: 8137965Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.Type: GrantFiled: December 14, 2010Date of Patent: March 20, 2012Assignee: DFB Technology Holdings, LLCInventors: Eric Rolland, Thomas Hunziker, Beatrice Mis, Christopher Rinsch
-
Publication number: 20120064041Abstract: The present invention provides methods and compositions for reprogramming mammalian mesenchymal stem cells, as well as to methods for using such cells, for example, to prevent or treat various injuries, diseases, and disorders in human and non-human animals.Type: ApplicationFiled: September 3, 2011Publication date: March 15, 2012Inventor: Arshak Alexanian
-
Alimentary Protein-Based Scaffolds (APS) for Wound Healing, Regenerative Medicine and Drug Discovery
Publication number: 20120058090Abstract: The invention provides engineered biomaterials derived from plant products. The engineered biomaterials are useful for biomedical applications. The engineered biomaterials are able to support the growth of animal cells.Type: ApplicationFiled: February 14, 2008Publication date: March 8, 2012Inventor: Peter Lelkes -
Publication number: 20120058119Abstract: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21 activity.Type: ApplicationFiled: November 14, 2011Publication date: March 8, 2012Applicant: Human Genome Sciences, Inc.Inventors: Steven M. Ruben, David Hilbert
-
Publication number: 20120009244Abstract: The introduction of the human NeuroD1 gene into human non-endocrine pancreatic epithelial cells (NEPECs) for producing insulin producing cells in vitro is described herein. Cytokeratin19 (CK19) positive NEPECs were transfected with plasmids encoding human NeuroD1 gene under human CK19 promoter. On characterization following the induction it was found that NEPEC+ND strongly expressed NeuroD1 and insulin mRNA. The ratio of NeuroD1 and human insulin positive cells in NEPEC+ND was significantly higher than NEPEC. Human insulin and C-peptide levels in culture media in NEPEC+ND were significantly higher than NEPEC. The findings demonstrate that human NeuroD1 under control of the CK19 promoter induces the differentiation of CK19 positive NEPECs into insulin producing cells.Type: ApplicationFiled: March 24, 2011Publication date: January 12, 2012Applicant: BAYLOR RESEARCH INSTITUTEInventors: Masayuki Shimoda, Shuyuan Chen, Hirofumi Noguchi, Shinichi Matsumoto, Paul A. Grayburn
-
Publication number: 20120009271Abstract: Stem cells are exposed to disease condition (the OGD stroke model), that mimics the target disease (stroke), allowing the stem cells to exert better neuroprotective effects. Thus, the present technology demonstrates a disease-tailored stem cell therapy. The present invention discloses that the administration of a therapeutically effective amount of amnion derived stem cells concomitantly with a therapeutically effective dose of melatonin provides additive/synergistic neuroprotective effects. Moreover, the present invention offers an equally robust technology employing a receptor-regulated mechanism, whereby stem cells can be enhanced (melatonin treatment) over their basal level (lack of melatonin treatment), facilitating a regulation of stem cells.Type: ApplicationFiled: September 12, 2011Publication date: January 12, 2012Applicants: MEDICAL COLLEGE OF GEORGIA, UNIVERSITY OF SOUTH FLORIDAInventors: Cesario V. Borlongan, Ornella Parolini
-
Patent number: 8084048Abstract: A tissue graft construct for use in repairing diseased or damaged tissues is provided. The tissue graft construct comprises a matrix composition selected from the group consisting of liver basement membrane and extracts and hydrolysates thereof, and processed collagen from vertebrate non-submucosal sources, added endothelial cells, and at least one additional preselected, exogenous population of cells which enhance the initiation of vessel-like structures in the grant. The preselected population of cells can be a population of non-keratinized or keratinized epithelial cells or a population of mesodermally derived cells selected from the group consisting of fibroblasts, smooth muscle cells, skeletal muscle cells, cardiac muscle cells, multi-potential progenitor cells, pericytes, osteogenic cells, and any other suitable cell type, preferably selected based on the tissue to be repaired.Type: GrantFiled: September 10, 2009Date of Patent: December 27, 2011Assignee: Purdue Research FoundationInventor: Stephen F. Badylak
-
Publication number: 20110300603Abstract: Method of enriching specific cells from cellular samples are disclosed, comprising contacting in solution a cellular sample with affinity-tagged ligands (ATLs) each comprising a first ligand linked to an affinity tag, wherein the ligand selectively binds a cellular marker of the rare cells and the affinity tag can be selectively captured by a capture moiety, wherein the affinity tags do not comprise a magnetic particle; and flowing the sample through a microfluidic device comprising the capture moiety to selectively retain ATL-bound cells. Methods for enriching circulating tumor cells, and devices for enriching specific cells from cellular samples are also disclosed.Type: ApplicationFiled: July 13, 2011Publication date: December 8, 2011Applicant: On-Q-ItyInventors: Allyn Forsyth, Helen Barnes
-
Publication number: 20110300628Abstract: The serum-free culture of normal human epithelial stem cells is of paramount importance for the in vitro formation of cloned human tissues by means of cell therapy. Several growth promoting agents are disclosed for use in a serum-free culture medium of normal human keratinocytes. Lithium ions, dibutryl-cyclic adenosine monophosphate, and prostaglandin E1 have been found effective as growth enhancing agents to be added singly or in combination, when used in combination with insulin-like growth factor-1. Lithium ions and prostaglandin E1 are disclosed as independent growth enhancing factors, that replace epidermal growth factor as a necessary growth factor required for keratinocyte clonal growth.Type: ApplicationFiled: June 1, 2011Publication date: December 8, 2011Inventor: JOHN JACOB WILLE, JR.
-
Publication number: 20110300627Abstract: The invention is directed to methods for reprogramming somatic cells to a less differentiated state. In particular, the invention is directed to methods for reprogramming amnion epithelial cells (AEC) including amnion-derived cells (ADC) and Amnion-derived Multipotent Progenitor cells (AMP cells) to a less differentiated state. The invention is further directed to compositions comprising reprogrammed AEC, ADC and AMP cells, and uses thereof.Type: ApplicationFiled: January 19, 2010Publication date: December 8, 2011Inventor: George L. Sing
-
Publication number: 20110293707Abstract: Use of the antimicrobial cathelicidin peptide II-37, N-terminal fragments of LL-37 or extended sequences of LL-37 having 1-3 amino acids in the C-terminal end, for stimulating proliferation of epithelial and stromal cells and thereby healing of wounds, such as chronic ulcers. The cytotoxic effect of LL-37 may be reduced by including a bilayer-forming polar lipid, especially a digalactosyldiacylglycerol, in pharmaceutical compositions and growth media comprising LL-37.Type: ApplicationFiled: July 28, 2011Publication date: December 1, 2011Inventors: Mona Ståhle-Bäckdahl, Johan Heilborn, Anders Carlsson, Conny Bogentoft
-
Publication number: 20110286985Abstract: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1, HIF-1?, or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into cultured skin tissue.Type: ApplicationFiled: August 1, 2011Publication date: November 24, 2011Applicant: STRATATECH CORPORATIONInventors: Allen R. Comer, B. Lynn Allen-Hoffmann
-
Publication number: 20110274662Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.Type: ApplicationFiled: October 10, 2008Publication date: November 10, 2011Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
-
Publication number: 20110268709Abstract: Tissues produced by culture of cells produced by nuclear transfer on a matrix derived from nuclear transfer embryos or embryos and pluripotent cells provided by other methods are provided. These tissues are useful for cell therapy.Type: ApplicationFiled: February 1, 2011Publication date: November 3, 2011Inventor: Robert Lanza
-
Publication number: 20110250684Abstract: In order to provide a method for producing neural stem cells easily and quickly by inducing differentiation of somatic cells directly into neurospheres, dedifferentiation factors are introduced into somatic cells, which are then cultured in suspension in the presence of growth factors to produce the neurospheres, thereby allowing the neural stem cells to be produced quickly without establishing iPS cells.Type: ApplicationFiled: November 4, 2009Publication date: October 13, 2011Applicant: KEIO UNIVERSITYInventors: Wado Akamatsu, Hideyuki Okano
-
Patent number: 8030068Abstract: The invention provides methods of culturing mammalian taste cells, including taste receptor cells. Cells are maintained for a duration of up to three months and longer while maintaining molecular and functional characteristics of mature taste cells. The cells are cultured on coated cell culture vessels and, from first replacement of medium onwards, the medium is replaced in intervals of at least 5 days. The invention further provides isolation and culturing methods of taste cells wherein the time that the cells are exposed to isolation solution and proteolytic enzymes is minimized and the cells are cultured in coated culture vessels with the medium replaced in intervals of at least 5 days from first replacement onwards. The invention further provides cultured taste cells, transfection and assay methods, and taste cell assay buffers with an osmolarity of about 300-320 and pH of about 7.0-7.3.Type: GrantFiled: January 2, 2009Date of Patent: October 4, 2011Assignee: Monell Chemical Senses CenterInventors: Nancy Ellen Rawson, Mehmet Hakan Ozdener
-
Publication number: 20110237643Abstract: The present invention is directed to the identification of a novel repressor located between ˜1.2 kb to ˜1.6 kb from the translation start site of the IFN-?1 promoter. The present invention provides a method of using siRNAs against ZEB1 (binds to the repressor region) and BLIMP-1 (binds outside the repressor region) and increases the promoter activity of IFN-?1 (i.e., increases the production of IFN-?1 protein). siRNAs against ZEB1 mRNA or BLIMP-1 mRNA increase IFN-?1 gene activity. There is provided a therapeutic application of siRNAs against ZEB1 and BLIMP-1 mRNAs in treating a mammal (including a human) by increasing the production of IFN-?1 protein that promotes an anti-viral response as well as treats asthma diseases.Type: ApplicationFiled: May 5, 2010Publication date: September 29, 2011Applicant: Medical Diagnostic Laboratories, L.L.C.Inventors: Grant Gallagher, Rachael Siegel, Joyce Eskdale
-
Publication number: 20110212541Abstract: Pathogenic effector proteins include one or more virulence motifs of amino acid consensus sequence BXZ, where B=RK or H; X=any amino acid or is absent; Z=L, M, I, W, Y or F) which bind to target polar lipids on a host (plant or animal) cell as a prerequisite for translocation of the pathogenic effector proteins into the cell. Translocation is prevented by binding blocking compounds to one or more motifs of the effector protein or to the lipid ligands of the host cell. The blocking compounds include synthetic or naturally occurring polypeptides which bind the polar lipids or the motifs, various polar lipids, the hydrophilic head-groups of polar lipids, etc. Suitable blocking compounds can be identified by assays demonstrating binding to the motifs or to the target polar lipids.Type: ApplicationFiled: November 11, 2010Publication date: September 1, 2011Applicant: Virginia Tech Intellectual Properties, Inc.Inventors: Brett Tyler, Shiv Kale, Vincenzo Antignani
-
Patent number: 7998737Abstract: The present invention relates to a cell culture medium comprising (a) an inhibitor of bone morphogenetic protein-4 (BMP-4) and (b) an inhibitor of pigment epithelium-derived factor (PEDF, also known as SerpinF1). In one embodiment, the inhibitors are antibodies against BMP-4 and PEDF, respectively. The medium allows to culture keratinocytes under non-differentiating conditions. The invention also relates to corresponding methods and kits. As the media and methods disclosed allow for an improved manufacture of keratinocytes, the invention also relates to the treatment of skin wounds and to the manufacture of corresponding medicaments. This will be of advantage for treatment e.g. of burns, ulcers, etc., in which transplantation of keratinocytes or skin is required.Type: GrantFiled: September 7, 2007Date of Patent: August 16, 2011Assignee: Deutsches KrebsforschungszentrumInventors: Axel Szabowski, Peter Angel, Julia Knebel
-
Patent number: 7985537Abstract: The present invention provides a method for determining hair inductive properties of a composition comprising injecting a composition comprising dissociated dermal cells and epidermal cells into skin of a mammal and determining whether at least one hair follicle forms.Type: GrantFiled: June 12, 2007Date of Patent: July 26, 2011Assignee: Aderans Research Institute, Inc.Inventors: Ying Zheng, Satish Parimoo, Kurt Stricker Stenn
-
Patent number: 7985587Abstract: The invention features methods of promoting hair growth in a subject. The methods include inducing or mimicking the effects of Wnt promoted signal transduction, e.g., by increasing the level of Wnt protein or administering an agent which mimics an effect of Wnt promoted signal transduction, e.g., by administering lithium chloride. Methods of inhibiting hair growth are also provided.Type: GrantFiled: February 2, 2007Date of Patent: July 26, 2011Assignee: The General Hospital CorporationInventors: Bruce A. Morgan, Jiro Kishimoto, Robert Burgeson
-
Patent number: 7972821Abstract: A method for the production of functional proteins including hormones by renal cells in a three dimensional culturing process responsive to shear stress uses a rotating wall vessel. Natural mixture of renal cells expresses the enzyme 1-?-hydroxylase which can be used to generate the active form of vitamin D: 1,25-diOH vitamin D3. The fibroblast cultures and co-culture of renal cortical cells express the gene for erythropoietin and secrete erythropoietin into the culture supernatant. Other shear stress response genes are also modulated by shear stress, such as toxin receptors megalin and cubulin (gp280). Also provided is a method of treating an in-need individual with the functional proteins produced in a three dimensional co-culture process responsive to shear stress using a rotating wall vessel.Type: GrantFiled: July 16, 2008Date of Patent: July 5, 2011Assignee: The United States of America as represented by the Administrator of the National Aeronautics and Space AdministrationInventors: Thomas John Goodwin, Timothy Grant Hammond, James Howard Kaysen
-
Patent number: 7955846Abstract: The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.Type: GrantFiled: May 17, 2005Date of Patent: June 7, 2011Assignee: The General Hospital CorporationInventors: Jonathan L. Tilly, Joshua Johnson
-
Patent number: 7955790Abstract: The present invention relates to in vitro cultured skin substitutes, and in particular to in vitro cultured skin substitutes that have improved barrier function. In some embodiments, improved barrier function is a result of improved culture conditions, while in other embodiments, improved barrier function results from genetic modification of keratinocytes. Improved culture conditions to improve barrier function include organotypic culture in the presence of linoleic acid and/or linoleic acid at about 75% humidity. Suitable genetic modifications for improving barrier function includes transfection with a DNA construct capable of expressing GKLF.Type: GrantFiled: July 16, 2008Date of Patent: June 7, 2011Assignee: Stratatech CorporationInventors: Allen Comer, Lynn Allen-Hoffmann, Michael Hoffmann
-
Publication number: 20110104735Abstract: The present invention discloses novel methods and omental, myocardial, liver, lung, renal, peritoneal, intestinal and pancreatic mesothelial cells which are useful for a number of procedures including drug discovery, co-culturing, cell therapy and bioassay. The invention provides a method for isolating these cells that improves upon the methods previously used and provides cells isolated in quantity. The present invention provides a list of secreted proteins from omentum mesothelial cells that can be utilized in the described cell based assays.Type: ApplicationFiled: November 1, 2010Publication date: May 5, 2011Inventors: BENJAMIN MARCUS BUEHRER, RICHARD BENTLEY CHEATHAM, JAMES BRADFORD NICOLL, PETER EARL PIERACCINI